Literature DB >> 21253758

Retinal functional changes measured by frequency-doubling technology in patients treated with hydroxychloroquine.

Lucia Tanga1, Marco Centofanti, Francesco Oddone, Mariacristina Parravano, Vincenzo Parisi, Lucia Ziccardi, Barbara Kroegler, Roberto Perricone, Gianluca Manni.   

Abstract

BACKGROUND: Antimalarial drugs such as chloroquine (CQ) and hydroxychloroquine (HCQ) are mainly used in the treatment of rheumatologic diseases, and their use may be associated with irreversible retinal toxicity. Previous studies indicate early paracentral visual field loss (Humphrey 10-2) in patients taking HCQ". These paracentral defects appear before changes in other clinical parameters as visual acuity and fundoscopy. The mechanism of CQ toxicity remains unclear. It was reported that toxic doses of CQ administered for as long as 4.5 years to Rhesus monkeys caused an initial dramatic effect on ganglion cells, followed later by photoreceptors and RPE degeneration. The purpose of this study is to explore early retinal functional changes measured by frequency-doubling technology (FDT) in patients treated with hydroxychloroquine (HCQ).
METHODS: Forty-eight eyes of 48 subjects treated with hydroxychloroquine (HCQ), with no signs of retinal toxicity, and 36 eyes of 36 age and sex-matched healthy subjects were enrolled in this cross-sectional, prospective, observational, case control study. Functional testing included frequency-doubling Humphrey-matrix perimetry (FDP), white-on-white Humphrey visual field perimetry (HFA), using the 24-2 and 10-2 threshold programs, multifocal electroretinogram (mfERG, Veris 4.9) and low contrast sensitivity (CS) measurement.
RESULTS: FDP mean deviation (MD) was found to be significantly reduced in HCQ-treated patients compared to controls both in the 24-2 (-1.38 ± 2.41 dB vs 0.21 ± 1.83 dB, p < 0.01) and in the 10-2 program (-0.97 ± 2.88 dB vs 0.15 ± 1.72 dB, p < 0.01). FDP pattern standard deviation (PSD) was found to be significantly worse in HCQ-treated patients compared to controls both in the 24-2 (2.70 ± 0.65 dB vs 2.41 ± 0.31 dB, p < 0.01 and in the 10-2 program (2.86 ± 0.48 dB vs 2.48 ± 0.39 dB, p < 0.01). HFA PSD and CS was also significantly reduced in HCQ patients, while response amplitude densities (RAD) were similar between patients and controls. A statistically significant difference in the ratio of the 5°-10° RAD and the 0°-2.5° RAD (0.31 ± 0.08 vs 0.36 ± 0.07 respectively, p < 0.05) was found between groups.
CONCLUSION: Frequency doubling perimetry could be useful to detect early retinal impairment in patients treated with hydroxychloroquine.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21253758     DOI: 10.1007/s00417-010-1612-6

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  22 in total

1.  Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of Ophthalmology.

Authors:  Michael F Marmor; Ronald E Carr; Michael Easterbrook; Ayad A Farjo; William F Mieler
Journal:  Ophthalmology       Date:  2002-07       Impact factor: 12.079

2.  Incidence of hydroxychloroquine retinopathy in 1,207 patients in a large multicenter outpatient practice.

Authors:  G D Levy; S J Munz; J Paschal; H B Cohen; K J Pince; T Peterson
Journal:  Arthritis Rheum       Date:  1997-08

3.  Learning effect of humphrey matrix frequency doubling technology perimetry in patients with ocular hypertension.

Authors:  Marco Centofanti; Paolo Fogagnolo; Francesco Oddone; Nicola Orzalesi; Michele Vetrugno; Gianluca Manni; Luca Rossetti
Journal:  J Glaucoma       Date:  2008-09       Impact factor: 2.503

4.  Chloroquine retinopathy. Early detection by retinal threshold test.

Authors:  R E Carr; P Gouras; R D Gunkel
Journal:  Arch Ophthalmol       Date:  1966-02

Review 5.  Ocular toxicity due to chloroquine and hydroxychloroquine: electrophysiological and visual function correlates.

Authors:  Radouil Tzekov
Journal:  Doc Ophthalmol       Date:  2005-01       Impact factor: 2.379

6.  Evaluation of several tests in screening for chloroquine maculopathy.

Authors:  S A Bishara; N Matamoros
Journal:  Eye (Lond)       Date:  1989       Impact factor: 3.775

7.  Hydroxychloroquine and chloroquine retinopathy: screening for drug toxicity.

Authors:  David J Browning
Journal:  Am J Ophthalmol       Date:  2002-05       Impact factor: 5.258

8.  Chloroquine retinopathy in the rhesus monkey.

Authors:  A R Rosenthal; H Kolb; D Bergsma; D Huxsoll; J L Hopkins
Journal:  Invest Ophthalmol Vis Sci       Date:  1978-12       Impact factor: 4.799

9.  Frequency doubling technology perimetry using a 24--2 stimulus presentation pattern.

Authors:  C A Johnson; G A Cioffi; E M Van Buskirk
Journal:  Optom Vis Sci       Date:  1999-08       Impact factor: 1.973

10.  Multifocal electroretinographic evaluation of long-term hydroxychloroquine users.

Authors:  Raj K Maturi; Minzhong Yu; Richard G Weleber
Journal:  Arch Ophthalmol       Date:  2004-07
View more
  6 in total

1.  Early morpho-functional changes in patients treated with hydroxychloroquine: a prospective cohort study.

Authors:  Giulio Ruberto; Carlo Bruttini; Carmine Tinelli; Lorenzo Cavagna; Alessandro Bianchi; Giovanni Milano
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-08-27       Impact factor: 3.117

2.  Single-session photodynamic therapy combined with intravitreal ranibizumab for neovascular age-related macular degeneration: a comprehensive functional retinal assessment.

Authors:  Mariacristina Parravano; Vincenzo Parisi; Lucia Ziccardi; Adele Chiaravalloti; Massimiliano Tedeschi; Andrea Cacciamani; Barbara Boccassini; Antonluca Boninfante; Monica Varano
Journal:  Doc Ophthalmol       Date:  2013-08-13       Impact factor: 2.379

3.  Scotoma analysis of 10-2 visual field testing with a red target in screening for hydroxychloroquine retinopathy.

Authors:  David J Browning; Chong Lee
Journal:  Clin Ophthalmol       Date:  2015-08-20

4.  Assessment of hydroxychloroquine maculopathy after cessation of treatment: an optical coherence tomography and multifocal electroretinography study.

Authors:  Marilita M Moschos; Eirini Nitoda; Irini P Chatziralli; Zisis Gatzioufas; Chryssanthi Koutsandrea; George Kitsos
Journal:  Drug Des Devel Ther       Date:  2015-06-11       Impact factor: 4.162

5.  Scotoma analysis of 10-2 visual field testing with a white target in screening for hydroxychloroquine retinopathy.

Authors:  David J Browning; Chong Lee
Journal:  Clin Ophthalmol       Date:  2015-05-27

6.  THE ROLE OF FREQUENCY DOUBLING TECHNOLOGY PERIMETRY IN EARLY DETECTION OF DIABETIC RETINOPATHY.

Authors:  Mario Bradvica; Dubravka Biuk; Ivanka Štenc Bradvica; Maja Vinković; Branimir Cerovski; Ivona Barać
Journal:  Acta Clin Croat       Date:  2020-03       Impact factor: 0.932

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.